Wall Street analysts forecast that Regeneron (REGN Quick QuoteREGN - Free Report) will report quarterly earnings of $11.75 per share in its upcoming release, pointing to a year-over-year increase of 1.4%. It is anticipated that revenues will amount to $3.67 billion, exhibiting an increase of 9.2% compared to the year-ago quarter.

Over the last 30 days, there has been an upward revision of 0.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

With that in mind, let's delve into the average projections of some Regeneron metrics that are commonly tracked and projected by analysts on Wall Street.

According to the collective judgment of analysts, 'Revenues- Other Revenue' should come in at $153.86 million. The estimate indicates a change of +11.5% from the prior-year quarter.

Analysts expect 'Revenues- Net product sales' to come in at $1.95 billion. The estimate indicates a year-over-year change of +9.4%.

It is projected by analysts that the 'Revenues- Collaboration' will reach $1.58 billion. The estimate indicates a year-over-year change of +9.9%.

Analysts' assessment points toward 'Revenues- Libtayo- Total' reaching $307.94 million. The estimate indicates a year-over-year change of +32.5%.

Analysts forecast 'Revenues- Eylea (Aflibercept)- US' to reach $1.58 billion. The estimate indicates a change of +9.3% from the prior-year quarter.

The average prediction of analysts places 'Revenues- Praluent (alirocumab)- US' at $43.25 million. The estimate points to a change of +7.1% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Revenues- Evkeeza- US' of $26.93 million. The estimate suggests a change of +41.8% year over year.

Based on the collective assessment of analysts, 'Revenues- Libtayo- ROW' should arrive at $109.25 million. The estimate indicates a change of +23.7% from the prior-year quarter.

The consensus estimate for 'Revenues- Libtayo- US' stands at $194.68 million. The estimate indicates a year-over-year change of +35.1%.

The consensus among analysts is that 'Revenues- Dupixent (dupilumab)- US' will reach $2.79 billion. The estimate indicates a year-over-year change of +18%.

The combined assessment of analysts suggests that 'Revenues- Kevzara (sarilumab)- ROW' will likely reach $46.85 million. The estimate indicates a year-over-year change of +8.2%.

Analysts predict that the 'Revenues- Kevzara (sarilumab)- US' will reach $63.57 million. The estimate indicates a year-over-year change of +21.3%.

View all Key Company Metrics for Regeneron here>>>

Over the past month, shares of Regeneron have returned -10.5% versus the Zacks S&P 500 composite's +2% change. Currently, REGN carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>